Cargando…

Yellow fever vaccine-associated viscerotropic disease: current perspectives

PURPOSE: To assess those published cases of yellow fever (YF) vaccine-associated viscerotropic disease that meet the Brighton Collaboration criteria and to assess the safety of YF vaccine with respect to viscerotropic disease. LITERATURE SEARCH: Ten electronic databases were searched with no restric...

Descripción completa

Detalles Bibliográficos
Autor principal: Thomas, Roger E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066857/
https://www.ncbi.nlm.nih.gov/pubmed/27784992
http://dx.doi.org/10.2147/DDDT.S99600
_version_ 1782460553510256640
author Thomas, Roger E
author_facet Thomas, Roger E
author_sort Thomas, Roger E
collection PubMed
description PURPOSE: To assess those published cases of yellow fever (YF) vaccine-associated viscerotropic disease that meet the Brighton Collaboration criteria and to assess the safety of YF vaccine with respect to viscerotropic disease. LITERATURE SEARCH: Ten electronic databases were searched with no restriction of date or language and reference lists of retrieved articles. METHODS: All abstracts and titles were independently read by two reviewers and data independently entered by two reviewers. RESULTS: All serious adverse events that met the Brighton Classification criteria were associated with first YF vaccinations. Sixty-two published cases (35 died) met the Brighton Collaboration viscerotropic criteria, with 32 from the US, six from Brazil, five from Peru, three from Spain, two from the People’s Republic of China, one each from Argentina, Australia, Belgium, Ecuador, France, Germany, Ireland, New Zealand, Portugal, and the UK, and four with no country stated. Two cases met both the viscerotropic and YF vaccine-associated neurologic disease criteria. Seventy cases proposed by authors as viscerotropic disease did not meet any Brighton Collaboration viscerotropic level of diagnostic certainty or any YF vaccine-associated viscerotropic disease causality criteria (37 died). CONCLUSION: Viscerotropic disease is rare in the published literature and in pharmacovigilance databases. All published cases were from developing countries. Because the symptoms are usually very severe and life threatening, it is unlikely that cases would not come to medical attention (but might not be published). Because viscerotropic disease has a highly predictable pathologic course, it is likely that viscerotropic disease post-YF vaccine occurs in low-income countries with the same incidence as in developing countries. YF vaccine is a very safe vaccine that likely confers lifelong immunity.
format Online
Article
Text
id pubmed-5066857
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50668572016-10-26 Yellow fever vaccine-associated viscerotropic disease: current perspectives Thomas, Roger E Drug Des Devel Ther Review PURPOSE: To assess those published cases of yellow fever (YF) vaccine-associated viscerotropic disease that meet the Brighton Collaboration criteria and to assess the safety of YF vaccine with respect to viscerotropic disease. LITERATURE SEARCH: Ten electronic databases were searched with no restriction of date or language and reference lists of retrieved articles. METHODS: All abstracts and titles were independently read by two reviewers and data independently entered by two reviewers. RESULTS: All serious adverse events that met the Brighton Classification criteria were associated with first YF vaccinations. Sixty-two published cases (35 died) met the Brighton Collaboration viscerotropic criteria, with 32 from the US, six from Brazil, five from Peru, three from Spain, two from the People’s Republic of China, one each from Argentina, Australia, Belgium, Ecuador, France, Germany, Ireland, New Zealand, Portugal, and the UK, and four with no country stated. Two cases met both the viscerotropic and YF vaccine-associated neurologic disease criteria. Seventy cases proposed by authors as viscerotropic disease did not meet any Brighton Collaboration viscerotropic level of diagnostic certainty or any YF vaccine-associated viscerotropic disease causality criteria (37 died). CONCLUSION: Viscerotropic disease is rare in the published literature and in pharmacovigilance databases. All published cases were from developing countries. Because the symptoms are usually very severe and life threatening, it is unlikely that cases would not come to medical attention (but might not be published). Because viscerotropic disease has a highly predictable pathologic course, it is likely that viscerotropic disease post-YF vaccine occurs in low-income countries with the same incidence as in developing countries. YF vaccine is a very safe vaccine that likely confers lifelong immunity. Dove Medical Press 2016-10-12 /pmc/articles/PMC5066857/ /pubmed/27784992 http://dx.doi.org/10.2147/DDDT.S99600 Text en © 2016 Thomas. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Thomas, Roger E
Yellow fever vaccine-associated viscerotropic disease: current perspectives
title Yellow fever vaccine-associated viscerotropic disease: current perspectives
title_full Yellow fever vaccine-associated viscerotropic disease: current perspectives
title_fullStr Yellow fever vaccine-associated viscerotropic disease: current perspectives
title_full_unstemmed Yellow fever vaccine-associated viscerotropic disease: current perspectives
title_short Yellow fever vaccine-associated viscerotropic disease: current perspectives
title_sort yellow fever vaccine-associated viscerotropic disease: current perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066857/
https://www.ncbi.nlm.nih.gov/pubmed/27784992
http://dx.doi.org/10.2147/DDDT.S99600
work_keys_str_mv AT thomasrogere yellowfevervaccineassociatedviscerotropicdiseasecurrentperspectives